

28 April 2026

Drugs used for respiratory issues and COPD (RBHSC) 28 04 2026

I have a freedom of information request that I need your help with. Could you please answer the questions below:

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- Benralizumab - 0
- Dupilumab - 6
- Omalizumab - 0
- Reslizumab - 0
- Mepolizumab - <5
- Tezepelumab - <5

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- Age 6-11 - <5
- Age 12-17 - 9
- Age 18 and above - 0

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

- Dupilumab – 7 (one patient was on Dupilumab and then switched to Tezepelumab in December 2025)
- Omalizumab

Q4. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with:

- Dupilumab - nil
- Mepolizumab – nil